Title:
ANTI-ILT4 ANTIBODY AND PHARMACEUTICAL USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2024/051804
Kind Code:
A1
Abstract:
The present invention provides an anti-ILT4 antibody and pharmaceutical use thereof.
More Like This:
| JP7445752 | Novel anti-PD-L1 antibody |
| WO/2004/106382 | ANTIBODY AND USE THEREOF |
| JP5612276 | T1R taste receptor and genes encoding it |
Inventors:
YE XIN (CN)
SUN LE (CN)
JIN XINSHENG (CN)
YING HUA (CN)
SUN LE (CN)
JIN XINSHENG (CN)
YING HUA (CN)
Application Number:
PCT/CN2023/117653
Publication Date:
March 14, 2024
Filing Date:
September 08, 2023
Export Citation:
Assignee:
JIANGSU HENGRUI PHARMACEUTICALS CO LTD (CN)
SHANGHAI HENGRUI PHARMACEUTICAL CO LTD (CN)
SHANGHAI HENGRUI PHARMACEUTICAL CO LTD (CN)
International Classes:
C07K16/28; A61K39/395; A61P35/00
Domestic Patent References:
| WO2022060767A1 | 2022-03-24 |
Foreign References:
| CN113056483A | 2021-06-29 | |||
| CN110719917A | 2020-01-21 | |||
| US20220056128A1 | 2022-02-24 |
Other References:
CHEN, XIAOZHENG ET AL.: "ILT4 Inhibition Prevents TAM- and Dysfunctional T Cell-Mediated Immunosuppression and Enhances the Efficacy of Anti-PD-L1 Therapy in NSCLC with EGFR Activation", THERANOSTICS, vol. 11, no. 7, 19 January 2021 (2021-01-19), XP055930689, DOI: 10.7150/thno.52435
Attorney, Agent or Firm:
GE CHENG & CO., LTD (CN)
Download PDF: